SNY Articles, Sanofi

On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructiv...

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negoti...

Sanofi SA (NASDAQ:SNY) is calling for initial bids for its $20 billion consumer health division. The French pharmaceutical giant is also considerin...

A bid by GSK Plc (NYSE:GSK) and other pharmaceutical companies to halt over 70,000 lawsuits in Delaware concerning the discontinued heartburn drug ...

Novavax (NASDAQ: NVAX) submitted an application to the FDA, seeking to amend its Emergency Use Authorization (EUA) and update its protein-based COV...

Monday, Sanofi SA (NASDAQ:SNY) shared data from the IMROZ phase 3 study of Sarclisa, which enrolled 446 patients with newly diagnosed, transplant-i...

On Monday, GSK Plc (NYSE:GSK) shares were down after the Delaware State Court ruled that more than 70,000 lawsuits could proceed over its discontin...

On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an a...

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...

A Chicago jury rejected an Illinois woman’s claim that the discontinued heartburn drug Zantac caused her colon cancer. This case is the first...